<DOC>
	<DOCNO>NCT01791426</DOCNO>
	<brief_summary>The objective investigation show performance Artelac Rebalance eye drop non-inferior Vismed eye drop subject moderate severe dry eye , assess safety Artelac Rebalance 90-day ( ± 10 day ) treatment administer 3 5 time per day .</brief_summary>
	<brief_title>A Study Evaluate Performance Safety Artelac Rebalance® Versus Vismed Management Dry Eye</brief_title>
	<detailed_description>Artelac Rebalance Vismed compliance European Directives ( CE mark ) product European Union ( EU ) .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects use tear substitute least 3 month prior inclusion , use preservativefree ART ( Artelac® UNO CL hypromellose 0.32 % w/v eye drop , single dose unit ) 6 time day least 2 week immediately prior randomization Subjects least 1 eye follow sign keratoconjunctivitis sicca 2 consecutive visit ( Visit 1 [ Screening ] Visit 2 [ Randomization ] ) Schirmer test without anesthesia ≤ 9 mm/5min Tear breakup time ≤ 10sec ( mean 3 measurement ) Total ocular surface stain score ≥ 4 ≤ 9 . This assessment combine corneal fluorescein stain nasal temporal bulbar conjunctival lissamine green staining , grade 05 accord Oxford Scheme Subjects decimal visual acuity ( VA ) habitual correction equal well 0.1 ( Snellen E chart ) eye Subjects receive stable systemic treatment ( unchanged 1 month longer ) Subjects moderate severe blepharitis Subjects severe ocular dryness accompany 1 following : Lid abnormality ( except mild blepharitis ) Corneal disease Ocular surface metaplasia Filamentary keratitis Corneal neovascularization Subjects currently wear contact lens wear contact lens within 90 day prior study start Subjects receive ocular surgery , include laser surgery , either eye within 180 day prior study start Subjects history ocular trauma , nondry eye ocular inflammation , ocular infection within 90 day prior study start Subjects history ocular allergic disease ocular herpes within 1 year prior study start Subjects history inflammatory ulcerative keratitis , recurrent corneal erosion , uveitis Subjects know hypersensitivity contraindication ingredient test comparator product Subjects plan initiation , change , concomitant medication could affect dry eye within 30 day Visit 1 ( Screening ) study Subjects receive ocular therapy ( either eye ) ophthalmic medication , except tear substitute , within 2 week prior study start Subjects expect receive ocular therapy study Subjects treat topical ocular steroidal nonsteroidal anti inflammatory medication within 30 day prior study start Subjects expect receive ocular therapy immunosuppressant ( eg , cyclosporine ) study use ocular immunosuppressant within 90 day prior study start Subjects receive occlusion therapy lacrimal punctum plug within 90 day prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>